Setting new standards in information exchange for the pharmaceutical and biotech industry
FDA Approves Immunotherapy Drug Opdivo to Treat Renal Cell Carcinoma
November 23, 2015
Congratulations to BMS who not only received FDA priority review status last week for Nivolumab (Opdivo) for Renal Cell Carcinoma, but have received today, FDA approval for the immunotherapy drug to treat the common form of kidney cancer in adults.
According to The National Cancer Institute, an estimated 61,560 new cases and 14,080 deaths resulted from kidney and renal pelvis cancer in the US this year.
The immunotherapy drug Opdivo provides an option for patients who have received prior anti-angiogenic therapy and has demonstrated increased survival rates in patients with the kidney disease.
Lead author of the NEJM article on renal cell carcinoma, Dr RJ Motzer of Memorial Sloan Kettering, will be delivering an in-depth talk on the most current phase III data for Nivolumab (Opdivo) for Renal Cell Carcinoma at the 2nd Annual Immuno-Oncology 360° conference, taking place February 2-3, 2016 at The New York Academy of Medicine.
To read the full article visit:
For more information on the 2nd Annual Immuno-Oncology 360° conference visit: